Cover Image
市場調查報告書

法布瑞氏症:開發中產品分析

Fabry Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200448
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
法布瑞氏症:開發中產品分析 Fabry Disease - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 81 Pages
簡介

法布瑞氏症是遺傳性疾病,是由於體內血管壁稱作globotriaosylceramide(GL-3)的特定脂肪物質異常堆積而發病。症候有疼痛,腹瀉,噁心,腎臟障礙,耳鳴,心律不整,心臟瓣膜症等,治療方法為使用酵素補充療法等。

本報告提供法布瑞氏症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

法布瑞氏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

法布瑞氏症:企業開發中的治療藥

法布瑞氏症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

法布瑞氏症:企業開發中的產品

法布瑞氏症的治療藥的開發企業

  • Actelion Ltd
  • Alexion Pharmaceuticals Inc
  • Amicus Therapeutics, Inc.
  • Genzyme Corporation
  • Greenovation Biotech GmbH
  • ISU ABXIS Co.,Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

法布瑞氏症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

法布瑞氏症:暫停中的計劃

法布瑞氏症:開發中止的產品

法布瑞氏症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8415IDB

Summary

Global Markets Direct's, 'Fabry Disease - Pipeline Review, H2 2016', provides an overview of the Fabry Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fabry Disease
  • The report reviews pipeline therapeutics for Fabry Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fabry Disease therapeutics and enlists all their major and minor projects
  • The report assesses Fabry Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fabry Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fabry Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fabry Disease Overview
  • Therapeutics Development
    • Pipeline Products for Fabry Disease - Overview
  • Fabry Disease - Therapeutics under Development by Companies
  • Fabry Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fabry Disease - Products under Development by Companies
  • Fabry Disease - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Alexion Pharmaceuticals Inc
    • Amicus Therapeutics, Inc.
    • Genzyme Corporation
    • Greenovation Biotech GmbH
    • ISU ABXIS Co.,Ltd.
    • JCR Pharmaceuticals Co., Ltd.
    • Neuraltus Pharmaceuticals, Inc.
    • Pharming Group N.V.
    • Protalix BioTherapeutics, Inc.
    • Sangamo BioSciences, Inc.
    • Shire Plc
  • Fabry Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • agalsidase beta biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVR-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enzyme Replacement Therapy + migalastat hydrochloride Biobetter - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibiglustat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lucerastat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • migalastat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOSS-AGAL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Alpha-Galactosidase A Replacement for Fabry Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzymes for Pompe, Fabry and Hunter Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBLSD-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fabry Disease - Dormant Projects
  • Fabry Disease - Discontinued Products
  • Fabry Disease - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2016: New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
      • Aug 10, 2016: Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
      • Aug 03, 2016: Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
      • Aug 02, 2016: Almac Group's Integrated Development to Commercialisation Services Support Amicus Therapeutics' First Commercial Orphan Drug Product
      • Jun 06, 2016: Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings
      • May 31, 2016: Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union
      • Apr 01, 2016: Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
      • Apr 01, 2016: First oral treatment for Fabry disease recommended for approval in the EU
      • Mar 22, 2016: Amicus Therapeutics Announces Expanded Access Program for Migalastat
      • Mar 03, 2016: Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium 2016
      • Mar 01, 2016: Amicus Therapeutics Highlights New Phase 3 Fabry Data at WORLDSymposium 2016
      • Feb 22, 2016: Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium 2016
      • Feb 10, 2016: Amicus Therapeutics Announces Presentations on Migalastat at 12th Annual WORLDSymposium 2016
      • Jan 11, 2016: Amicus Therapeutics Provides Update On Migalastat for Fabry Disease
      • Nov 16, 2015: Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fabry Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Fabry Disease - Pipeline by Actelion Ltd, H2 2016
  • Fabry Disease - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Fabry Disease - Pipeline by Amicus Therapeutics, Inc., H2 2016
  • Fabry Disease - Pipeline by Genzyme Corporation, H2 2016
  • Fabry Disease - Pipeline by greenovation Biotech GmbH, H2 2016
  • Fabry Disease - Pipeline by ISU ABXIS Co.,Ltd., H2 2016
  • Fabry Disease - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2016
  • Fabry Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2016
  • Fabry Disease - Pipeline by Pharming Group N.V., H2 2016
  • Fabry Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Fabry Disease - Pipeline by Sangamo BioSciences, Inc., H2 2016
  • Fabry Disease - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Fabry Disease - Dormant Projects, H2 2016
  • Fabry Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Fabry Disease, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top